Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
Presentation to Highlight Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction
LOS ALTOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Company management will participate at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York City. Shalabh Gupta, M.D., Chairman and Chief Executive Officer of Unicycive, will virtually present a corporate overview, which will be available On-Demand beginning at 7:00 am ET on Monday, September 12, 2022 through the end of the conference.
A webcast of Dr. Gupta’s presentation will also be available on the Investors section of the Unicycive website at https://ir.unicycive.com/events-presentations/ir-calendar, where it will be available for approximately 90 days following the event.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.
Investor Contact:
ir@unicycive.com
(650) 900-5470
Anne Marie Fields
Stern Investor Relations
annemarie.fields@sternir.com
212-362-1200
SOURCE: Unicycive Therapeutics, Inc.
Released September 6, 2022